Cited 0 times in
Efficacy and safety of micafungin as an empirical antifungal agent for febrile neutropenic patients with hematological diseases.
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Park, JS | - |
dc.contributor.author | Kim, DH | - |
dc.contributor.author | Choi, CW | - |
dc.contributor.author | Jeong, SH | - |
dc.contributor.author | Choi, JH | - |
dc.contributor.author | Kim, K | - |
dc.contributor.author | Kim, SJ | - |
dc.contributor.author | Jung, CW | - |
dc.contributor.author | Yang, DH | - |
dc.contributor.author | Jang, JH | - |
dc.date.accessioned | 2011-05-17 | - |
dc.date.available | 2011-05-17 | - |
dc.date.issued | 2010 | - |
dc.identifier.issn | 0001-5792 | - |
dc.identifier.uri | http://repository.ajou.ac.kr/handle/201003/2611 | - |
dc.description.abstract | BACKGROUND: This observational study was conducted to document the efficacy and safety of the use of micafungin (Mycamine) as an empirical antifungal agent in febrile neutropenic patients.
METHODS: Micafungin was administered for sustained fever (>38.4°C) on days 3-5 following the initiation of empirical antibiotic therapy. The overall success rate and side effects were evaluated. RESULTS: A total of 47 patients with acute myeloid leukemia, acute lymphoblastic leukemia, myelodysplastic syndrome and lymphoma were enrolled in the study. The overall success rate of micafungin was 61.7% (29/47). A total of 3 patients (6.4%) experienced grade 3/4 elevations in their aspartate aminotransferase levels, and 10 patients (21%) experienced grade 3/4 hyperbilirubinemia, 9 of which resolved. Four patients died of septic shock. Younger patients (<50 years) and patients with acute lymphoblastic leukemia exhibited a better response to micafungin than other patients. Patients that were less profoundly neutropenic (≥0.05 × 10(9)/l) also had a better response to micafungin, as did the patients who recovered from their fever or neutropenia. CONCLUSION: Micafungin has an excellent efficacy (61.7%) and safety profile when used as an empirical antifungal agent in febrile neutropenic patients with hematological disorders. | - |
dc.language.iso | en | - |
dc.subject.MESH | Adolescent | - |
dc.subject.MESH | Adult | - |
dc.subject.MESH | Aged | - |
dc.subject.MESH | Aged, 80 and over | - |
dc.subject.MESH | Anti-Bacterial Agents | - |
dc.subject.MESH | Antifungal Agents | - |
dc.subject.MESH | Echinocandins | - |
dc.subject.MESH | Female | - |
dc.subject.MESH | Fever | - |
dc.subject.MESH | Humans | - |
dc.subject.MESH | Immunocompromised Host | - |
dc.subject.MESH | Leukemia, Myeloid, Acute | - |
dc.subject.MESH | Lipopeptides | - |
dc.subject.MESH | Lymphoma | - |
dc.subject.MESH | Male | - |
dc.subject.MESH | Middle Aged | - |
dc.subject.MESH | Mycoses | - |
dc.subject.MESH | Myelodysplastic Syndromes | - |
dc.subject.MESH | Neutropenia | - |
dc.subject.MESH | Precursor Cell Lymphoblastic Leukemia-Lymphoma | - |
dc.subject.MESH | Prospective Studies | - |
dc.subject.MESH | Young Adult | - |
dc.title | Efficacy and safety of micafungin as an empirical antifungal agent for febrile neutropenic patients with hematological diseases. | - |
dc.type | Article | - |
dc.identifier.pmid | 20664196 | - |
dc.identifier.url | http://content.karger.com/produktedb/produkte.asp?DOI=000315558&typ=pdf | - |
dc.contributor.affiliatedAuthor | 박, 준성 | - |
dc.contributor.affiliatedAuthor | 정, 성현 | - |
dc.contributor.affiliatedAuthor | 최, 진혁 | - |
dc.type.local | Journal Papers | - |
dc.identifier.doi | 10.1159/000315558 | - |
dc.citation.title | Acta haematologica | - |
dc.citation.volume | 124 | - |
dc.citation.number | 2 | - |
dc.citation.date | 2010 | - |
dc.citation.startPage | 92 | - |
dc.citation.endPage | 97 | - |
dc.identifier.bibliographicCitation | Acta haematologica, 124(2). : 92-97, 2010 | - |
dc.identifier.eissn | 1421-9662 | - |
dc.relation.journalid | J000015792 | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.